whatshot

RPTX   $3.43  2.39% Market Closed

Repare Therapeutics Inc
show_chart Advanced Chart of RPTX
Last Events:

2023-08-06 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the oversold territory and it grows. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bullish reversal to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2023-08-06 Trend Power changed from almost flat to slow.

2023-08-05 Signal in RSI changed from bearish recovery to bullish reversal. RSI indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the overbought zone.

2023-08-04 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: main and signal line crossing.

2023-08-04 Trend Power changed from slow to almost flat.

2023-08-02 Trend pattern changed from симметричный треугольник to нисходящий треугольник.

2023-08-02 Signal in RSI changed from bullish reversal to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

Current temperature: 8.45
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 7
Target Price Mean 13.71
Mean unverified/preliminary 13.71 / 13.71
Target Price Low / High 8.00 / 25.00
Median / STD DEV 10.00 / 6.87
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None None None
rsi Sell None None
macd None ActivelyBuy None
stoch ActivelyBuy None None
ma20 Sell Sell None
ma50 ActivelyBuy None None
ma100 None Sell None
Candlestick PatternOct. 18, 2024 Three Stars -
ISIN US7602731025
ceo Mr. Lloyd Mitchell Segal
Website https://www.reparerx.com
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase I/Ib clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; with Foundation Medicine, Inc. for the provision of prospective genomic profiling of lunresertib alone or in combinations in genomically-defined patient populations; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.